First trial

The chart shows the growth of an initial investment of $10,000 in First trial, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced Every 3 months.

Based on dividend-adjusted daily data since Feb 24, 2025, First trial's average daily return is +0.14%, while the average monthly return is +2.76%. At this rate, an investment would double in approximately 2.1 years.

Historically, 76% of months were positive and 24% were negative. The best month was Apr 2026 with a return of +9.8%, while the worst month was Mar 2025 at -3.9%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 3 months.

On a daily basis, First trial closed higher 59% of trading days. The best single day was Apr 9, 2025 with a return of +7.0%, while the worst single day was Apr 4, 2025 at -4.9%.

First trial has an annualized alpha of 22.56%, beta of 0.81, and R2 of 0.81 versus S&P 500 Index. Calculated based on daily prices since February 24, 2025.

• This portfolio captured 152.03% of S&P 500 Index gains but only 46.74% of its losses - a favorable profile for investors.
• This portfolio generated an annualized alpha of 22.56% versus S&P 500 Index - delivering returns beyond what market exposure alone would predict.

First trial has an expense ratio of 0.05%, which is considered low. Below, you can find the expense ratios of the portfolio's funds side by side and easily compare their relative costs.

First trial ranks 98 for risk / return — in the top 98% of Portfolios on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk. Learn how to interpret the Sharpe ratio.

The current First trial Sharpe ratio is 4.35 as of Jun 16, 2026 (the value is recalculated daily), calculated over the past 12 months.

Compared to the broad market, where average Sharpe ratios range from 1.72 to 2.63, this portfolio's current Sharpe ratio is in the top 25%. This signifies superior risk-adjusted performance, meaning the portfolio is delivering strong returns for the level of risk taken compared to most others.

The chart below shows the rolling Sharpe ratio of First trial compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.

First trial provided a 1.21% dividend yield over the last twelve months.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the First trial. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the First trial was 14.39%, occurring on Apr 8, 2025. Recovery took 43 trading sessions.

The chart below shows the rolling one-month volatility.